Sera Prognostics, Inc. (NASDAQ:SERA – Free Report) insider John J. Boniface sold 5,022 shares of the company’s stock on Wednesday, August 7. The shares were sold at an average price of $7.42, for a total value of $37,263.24. Following the sale, the insider now directly owns 129,847 shares of the company’s stock, valued at approximately $963,464.74. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Sera Prognostics price-performance ratio
NASDAQ:SERA shares traded $0.01 lower on Friday, reaching $7.40. The company’s trading volume was 75,158 shares, compared to its average volume of 144,807. The company has a 50-day moving average of $7.24 and a 200-day moving average of $8.42. Sera Prognostics, Inc. has a 1-year low of $1.52 and a 1-year high of $12.35. The company has a market cap of $241.64 million, a P/E ratio of -6.92, and a beta of 1.06.
Sera Prognostics (NASDAQ:SERA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7. The company reported earnings per share ($0.25) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.08 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.35%. In the same quarter last year, the company reported earnings per share ($0.34). On average, equities analysts expect that Sera Prognostics, Inc. will post earnings per share of -$0.94 for the current fiscal year.
Changes in analyst ratings
Separately, William Blair reiterated an “outperform” rating on shares of Sera Prognostics in a report on Friday, May 10.
Read our latest report on SERA
Hedge funds comment on Sera Prognostics
Several institutional investors have recently changed their holdings in the company. Renaissance Technologies LLC acquired a new position in Sera Prognostics in the 2nd quarter valued at approximately $162,000. American Century Companies Inc. increased its position in Sera Prognostics by 12.7% in the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after purchasing an additional 2,891 shares in the last quarter. Ballentine Partners LLC acquired a new position in Sera Prognostics in the 2nd quarter valued at approximately $294,000. Lake Street Advisors Group LLC acquired a new position in Sera Prognostics in the 2nd quarter valued at approximately $144,000. Finally, Rhumbline Advisers acquired a new stake in shares of Sera Prognostics in the 2nd quarter valued at approximately $190,000. 54.64% of the shares are currently owned by institutional investors.
About Sera Prognostics
(Get free report)
Sera Prognostics, Inc., a women’s health diagnostics company, discovers, develops and commercializes biomarker tests to improve pregnancy outcomes in the United States. The company is developing the PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
More information
Get daily news and reviews about Sera Prognostics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sera Prognostics and related companies with MarketBeat.com’s FREE daily email newsletter.
